SGX Pharmaceuticals Report issue

For profit Phase 1 Phase 2
Founded: San Diego CA United States (1998)
Status: Acquired by Eli Lilly (2008)

Organization Overview

First Clinical Trial
2003
NCT00104286
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 2 Trials (1)

troxatyl (3 trials)

Drugs in Phase 1 Trials (1)

sgx523 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 2